An observational study in Surgery, Liver Tumor and Pancreas Tumor, sponsored by Methodist Health System. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Methodist Health System · Observational
The objective of this study is to compare open and minimally invasive pancreatic and liver resection techniques and analyze the different outcome variables from the clinical standpoint.
The plan is to investigate patient survival, length of stay, complication rates, operative time, transfusion rate, 30 and 90-day readmission rate, and hospital charges.
The plan is to conduct a retrospective chart review of patients who have undergone pancreatic and liver resection by using Meditech and Epic. A non-identified database will be created after retrospectively reviewing each patient case involving pancreatic or liver resection at MDMC. The study period will start in January 2006 until December 2020. Variables will include demographics, clinical disease diagnoses, and operative parameters as well as indirect charges from the hospitalizations.
3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 954 are open to participants now.
This study's planned enrollment of 431 is above the median of 200 across 754 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Methodist Health System is the lead sponsor of 169 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
pancreatic or liver resection surgeries from January 2006 until December 2020 at Methodist Dallas Medical Center (MDMC)
Exclusion Criteria:
to compare open versus minimally invasive pancreatic resection techniques and analyze the different outcome variables from the clinical standpoint
Also known as: minimally invasive pancreatic resection techniques
Patient Survival
It will be calculated in days.Minimally invasive techniques are being adopted for complex pancreatic and liver surgery and there is a need to understand if these techniques are advantageous to the patient, if the cost is justified and if the risks are acceptable when compared to the gold standard open surgery.
Time frame: through study completion, an average of 1 year
Length of stay
It will be calculated in days. The days stayed in hospital post-procedure.
Time frame: Up to 1 year
Complication rates
Patient may visit physician or hospital for any symptoms or may need hospitalizations.
Time frame: through study completion, an average of 1 year
Operative time
The time required for the procedure.
Time frame: up to 10 hours
Transfusion rate
If any post-procedure transfusion required, will be recorded.
Time frame: through study completion, an average of 1 year
30 and 90 day readmission rate
After the procedure any hospital admissions up to 30 days will be recorded.
Time frame: through study completion, an average of 1 year
Hospital charges
The hospital charges for the procedure will be recorded.
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Methodist Health System